1
|
Pondugula SR, Flannery PC, Apte U, Babu JR, Geetha T, Rege SD, Chen T, Abbott KL. Mg2+/Mn2+-dependent phosphatase 1A is involved in regulating pregnane X receptor-mediated cytochrome p450 3A4 gene expression. Drug Metab Dispos 2015; 43:385-91. [PMID: 25561723 PMCID: PMC11024896 DOI: 10.1124/dmd.114.062083] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 01/05/2015] [Indexed: 04/20/2024] Open
Abstract
Variations in the expression of human pregnane X receptor (hPXR)-mediated cytochrome p450 3A4 (CYP3A4) in liver can alter therapeutic response to a variety of drugs and may lead to potential adverse drug interactions. We sought to determine whether Mg(2+)/Mn(2+)-dependent phosphatase 1A (PPM1A) regulates hPXR-mediated CYP3A4 expression. PPM1A was found to be coimmunoprecipitated with hPXR. Genetic or pharmacologic activation of PPM1A led to a significant increase in hPXR transactivation of CYP3A4 promoter activity. In contrast, knockdown of endogenous PPM1A not only attenuated hPXR transactivation, but also increased proliferation of HepG2 human liver carcinoma cells, suggesting that PPM1A expression levels regulate hPXR, and that PPM1A expression is regulated in a proliferation-dependent manner. Indeed, PPM1A expression and hPXR transactivation were found to be significantly reduced in subconfluent HepG2 cells compared with confluent HepG2 cells, suggesting that both PPM1A expression and hPXR-mediated CYP3A4 expression may be downregulated in proliferating livers. Elevated PPM1A levels led to attenuation of hPXR inhibition by tumor necrosis factor-α and cyclin-dependent kinase-2, which are known to be upregulated and essential during liver regeneration. In mouse regenerating livers, similar to subconfluent HepG2 cells, expression of both PPM1A and the mouse PXR target gene cyp3a11 was found to be downregulated. Our results show that PPM1A can positively regulate PXR activity by counteracting PXR inhibitory signaling pathways that play a major role in liver regeneration. These results implicate a novel role for PPM1A in regulating hPXR-mediated CYP3A4 expression in hepatocytes and may explain a mechanism for CYP3A repression in regenerating livers.
Collapse
Affiliation(s)
- Satyanarayana R Pondugula
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| | - Patrick C Flannery
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| | - Udayan Apte
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| | - Jeganathan Ramesh Babu
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| | - Thangiah Geetha
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| | - Shraddha D Rege
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| | - Taosheng Chen
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| | - Kodye L Abbott
- Department of Anatomy, Physiology, and Pharmacology (S.R.P., P.C.F., K.L.A.) and Department of Nutrition, Dietetics, and Hospitality Management (J.R.B., S.D.R.), Auburn University, Auburn, Alabama; Department of Chemistry (T.G.), Auburn University at Montgomery, Montgomery, Alabama; Department of Chemical Biology and Therapeutics (T.C.), St. Jude Children's Research Hospital, Memphis, Tennessee; and Department of Pharmacology, Toxicology, and Therapeutics (U.A.), University of Kansas, Kansas City, Kansas
| |
Collapse
|
2
|
Ghosh MK, Patra F, Ghosh S, Hossain CM, Mukherjee B. Antisense oligonucleotides directed against insulin-like growth factor-II messenger ribonucleic acids delay the progress of rat hepatocarcinogenesis. J Carcinog 2014; 13:2. [PMID: 24737950 PMCID: PMC3986617 DOI: 10.4103/1477-3163.126761] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2013] [Accepted: 11/17/2013] [Indexed: 02/05/2023] Open
Abstract
Background: Hepatocellular carcinoma (HCC) is a multistep complex process, caused by many of genetic alteration. Insulin-like growth factors and their receptor have been widely implicated to HCC. Insulin-like growth factor-II (IGF-II) is a mitogenic polypeptide, found in various fetal and neonatal tissues of humans and rats and expresses in HCC. Here we investigated anticancer potential of phosphorothioate antisense oligonucleotides (ASOs) against three coding exons (exon-1/exon-2/exon-3) of IGF-II messenger ribonucleic acid in rat hepatocarcinogenesis model. Materials and Methods: During diethylnitrosamine and 2-acetylaminofluorene induced hepatocarcinogenesis, rats were treated with ASOs. Various biochemical and histological studies were conducted. Results: About 40% of carcinogen treated rats, which received two oligomers (against exon-1 or-3) did not show any hepatic lesion, hyperplastic nodule or tumor and remaining 60% of those rats showed lesion incidence and had about 59% and 55% reductions in the numbers of hepatic altered foci, respectively. Reductions in the total lesion-area when compared with carcinogen control rats were 64% and 53%, respectively for the animals treated with carcinogen and received the ASOs against exon-1/-3. Fluorescein isothiocyanate-labeled ASO reached in the hepatocytes in 2 h. No predominant IGF-II overexpression was observed in case of rats treated with the two ASOs. Treatment of the antisense IGF-II oligomers in carcinogen treated rats show better hepatocellular integrity along with several preneoplastic/neoplastic marker isoenzyme/enzyme modulations. Conclusions: Two of the three antisense oligomer-types effectively controlled IGF-II overexpression, causing the delay of the development and/or progress of hepatic cancer in rats.
Collapse
Affiliation(s)
- Miltu Kumar Ghosh
- Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India ; Georg-August-Universität Göttingen, Department of Human Genetics, Heinrich-Düker Weg 12, 37073 Göttingen, Germany
| | - Falguni Patra
- Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | - Shampa Ghosh
- Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| | | | - Biswajit Mukherjee
- Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India
| |
Collapse
|
4
|
Pondugula SR, Dong H, Chen T. Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression. Expert Opin Drug Metab Toxicol 2009; 5:861-73. [PMID: 19505191 DOI: 10.1517/17425250903012360] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND The expression of drug-metabolizing enzymes CYPs is controlled by pregnane X receptor (PXR), and, therefore, understanding how PXR modulates CYP expression is important to minimize adverse drug interactions, one type of preventable adverse drug reaction. OBJECTIVE We review the mechanisms of PXR-mediated repression of CYP expression. METHODS We discuss the clinical implications of CYP repression and the role of signal cross-talks, including protein-protein interactions and phosphorylation of PXR and coregulators, in inhibiting PXR and repressing CYP expression. RESULTS/CONCLUSION Kinases such as cyclin-dependent kinase 2, protein kinase A, PKC and 70 kDa form of ribosomal protein S6 kinase repress CYP expression by phosphorylating and inhibiting PXR. Growth factor signaling represses CYP expression by phosphorylating and inhibiting forkhead in rhabdomyosarcoma, a co-activator of PXR. During inflammation, NF-kappaB represses both PXR and CYP expression through protein-protein interactions with the PXR pathway.
Collapse
Affiliation(s)
- Satyanarayana R Pondugula
- St. Jude Children's Research Hospital, Department of Chemical Biology and Therapeutics, 262 Danny Thomas Place, Mail Stop 1000, Memphis, TN 38105, USA
| | | | | |
Collapse
|
5
|
Le Vee M, Lecureur V, Moreau A, Stieger B, Fardel O. Differential regulation of drug transporter expression by hepatocyte growth factor in primary human hepatocytes. Drug Metab Dispos 2009; 37:2228-35. [PMID: 19661216 DOI: 10.1124/dmd.109.028035] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Hepatocyte growth factor (HGF) is known to down-regulate expression of drug-detoxifying proteins such as cytochromes P450 (P450s) in human hepatocytes. The present study was designed to determine whether HGF may also impair expression of uptake and efflux drug transporters, which constitute important determinants of the liver detoxification pathway, such as P450s. Exposure of primary human hepatocytes to 20 ng/ml HGF for 48 h was found to down-regulate mRNA levels of major sinusoidal uptake transporters, including sodium taurocholate-cotransporting polypeptide (NTCP), organic anion-transporting polypeptide (OATP) 2B1, OATP1B1, organic cation transporter (OCT) 1, and organic anion transporter 2. HGF concomitantly reduced NTCP, OATP2B1, and OATP1B1 protein expression and NTCP, OATP, and OCT1 transport activities. With respect to efflux pumps, HGF decreased mRNA expression of the canalicular bile salt export pump, whereas that of the multidrug resistance (MDR) 1 gene was transiently increased. Moreover, Western blot analysis indicated that HGF up-regulated expressions of MDR1/P-glycoprotein and breast cancer resistance protein in human hepatocytes, whereas those of multidrug resistance gene-associated protein (MRP) 2 and MRP3 were unchanged. However, HGF prevented constitutive androstane receptor-related up-regulation of MRP2 occurring in phenobarbital-treated hepatocytes. Taken together, these data demonstrate that HGF differentially regulates transporter expression in human hepatocytes, i.e., it represses most of the sinusoidal uptake transporters, whereas expression of most of the efflux transporters is unchanged or increased. Such changes probably contribute to alterations of pharmacokinetics in patients with diseases associated with increased plasma levels of HGF such as fulminant hepatitis.
Collapse
Affiliation(s)
- Marc Le Vee
- Equipe d'Accueil 4427, SeRAIC/Institut National de la Santé et de la Recherche Médicale U620, Institut Fédératif de Recherches 140, University of Rennes 1, Rennes, France
| | | | | | | | | |
Collapse
|
6
|
Kakizaki S, Yamazaki Y, Kosone T, Horiguchi N, Horigichi N, Sohara N, Sato K, Takagi H, Yoshinari K, Mori M. Gene expression profiles of drug-metabolizing enzymes and transporters with an overexpression of hepatocyte growth factor. Liver Int 2007; 27:109-19. [PMID: 17241389 DOI: 10.1111/j.1478-3231.2006.01384.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND It is important to elucidate the precise mechanism of drug metabolism during hepatic regeneration. Although cytochromes P450 (CYPs) are well known to be down-regulated in growth-stimulated cells, the overall gene expression profile of drug metabolizing enzymes are still not fully understood during hepatic regeneration. In this study, we investigated the gene expression profiles of such enzymes with an overexpression of hepatocyte growth factor (HGF). METHODS Gene expression profiles were obtained using the Affymetrix MOE430A GeneChip oligonucleotide microarray by comparing HGF transgenic mice and wild-type mice. RESULTS HGF produced a general decrease in mice with the expression of CYP isoforms such as Cyp1a2, Cyp2b10, Cyp2c, Cyp2d9, Cyp3a11, Cyp4a10, and Cyp7a1. Some isoforms of alcohol dehydrogenase, aldehyde dehydrogenase, and carboxylesterase also decreased. In the phase II enzymes, some isoforms of glutathione S-transferase and UDP-glucuronosyl transferase showed a reduced expression, although the sulfotransferase did not. In phase III transporters, some organic anion transporter and organic cation transporters were down-regulated. Among the nuclear receptors that are known to regulate the drug-metabolizing enzymes, small heterodimer partner and constitutive androstane receptor were down-regulated with an HGF overexpression. The protein level and enzymatic activity of Cyp2c decreased with an HGF overexpression. We furthermore investigated the inducibility of Cyp2b10 with xenobiotic inducers. Although the basal expression of Cyp2b10 was repressed, the inducibility was not abolished with the HGF overexpression. CONCLUSIONS HGF down-regulated not only CYPs but also some drug-metabolizing enzymes, transporters, and nuclear receptors. We thus have to take in our mind the low basal expression of drug metabolizing enzymes, when treating patients with a regenerative liver state.
Collapse
Affiliation(s)
- Satoru Kakizaki
- Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Grieco A, Castellano R, Matera A, Marcoccia S, Di Rocco P, Ragazzoni E, Vecchio FM, Gasbarrini G. Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients. J Gastroenterol Hepatol 1998; 13:460-6. [PMID: 9641640 DOI: 10.1111/j.1440-1746.1998.tb00668.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Antipyrine metabolism is widely used as an index of the drug-metabolizing reserve of the liver. It is well known that metabolism of this drug is impaired in subjects with acute hepatitis or cirrhosis, but conflicting data have been reported regarding patients with chronic postinfectious hepatitis or liver cancer. We studied conventional liver-function parameters and antipyrine metabolism (antipyrine per o.s. 18 mg/kg) in 518 subjects. One hundred and one patients had liver metastases (various primaries). Based on the number and size of lesions, the hepatic involvement was considered minimal in 47 and massive in 54 (groups B1 and B2, respectively). One hundred and two had chronic active hepatitis (CAH); 51 patients with histological evidence of fibrosis/early cirrhosis and 51 patients were without histological evidence of fibrosis/early cirrhosis. Ninety-two had histologically confirmed cirrhosis (group D), and the remaining 120 had cirrhosis and hepatocellular carcinoma (group E). The control group was composed of 103 subjects with healthy livers (group A). Antipyrine clearance (AP Cl) in CAH patients with fibrosis (0.246 +/- 0.98 mL/min per kg) was similar to that observed in patients with cirrhosis (0.223 +/- 0.148 mL/min per kg), and both values were significantly lower than that found in CAH patients without fibrosis (0.406 +/- 0.159 mL/min per kg, P < 0.01). Antipyrine clearance in patients with liver metastases (0.426 +/- 0.174 mL/min per kg) was similar to that of the healthy group (0.489 +/- 0.210 mL/min per kg). Cirrhotics and cirrhotics with hepatocellular carcinoma (HCC) presented similar degrees of impairment. Antipyrine clearance was positively correlated with serum albumin (r2 = 0.10, P = 0.01) and prothrombin time (r2 = 0.129, P < 0.01) in all groups, except those with liver metastases. In patients with CAH, the presence of fibrosis/cirrhosis is associated with impaired antipyrine metabolism. The lack of impairment in groups with liver metastases suggests that the functional hepatic reserve is maintained even in the presence of massive neoplastic invasion.
Collapse
Affiliation(s)
- A Grieco
- Department of Internal Medicine and Geriatrics, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Hagiwara A, Matsuda T, Tamano S, Kitano M, Imaoka S, Funae Y, Takesada Y, Shirai T, Fukushima S. Dose-related increases in quantitative values for altered hepatocytic foci and cytochrome P-450 levels in the livers of rats exposed to phenobarbital in a medium-term bioassay. Cancer Lett 1996; 110:155-62. [PMID: 9018095 DOI: 10.1016/s0304-3835(96)04478-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The dose-response relationship between liver tumor promoting activity and cytochrome P-450 (CYP) induction by phenobarbital sodium (PB) was investigated using the liver medium-term bioassay system of Ito. Two weeks after a single dose of N-nitrosodiethylamine (DEN) (200 mg/kg body weight, i.p.), rats were given PB at dietary levels of 500, 250, 125, 60, 30, 15 and 8 parts per million (ppm) for 6 weeks. All rats were subjected to partial hepatectomy at week 3, and were killed at week 8. Quantitative values for glutathione S-transferase placental form positive hepatocytic (GST-P+) foci were increased in the high dose groups dose-dependently. In contrast, the values in the low dose groups were rather lower than that of the control. CYP2B1, 2C6 and 3A2 were predominantly immunostainable in hepatocytes around the central vein. While Western blotting revealed CYP2B1 and 2C6 proteins to be increased with strict dose-dependence, CYP3A2 was only elevated at high doses. Thus, a good correlation between increase of GST-P+ foci and CYP3A2 induction was observed, as well as with CYP2B1 and 2C6 in high dose groups.
Collapse
Affiliation(s)
- A Hagiwara
- Daiyu-kai Institute of Medical Science, Nishiazai, Azai-cho, Ichinomiya, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|